NI200900203A - Sales novedosas de piperazina como antagonistas d3/d2. - Google Patents

Sales novedosas de piperazina como antagonistas d3/d2.

Info

Publication number
NI200900203A
NI200900203A NI200900203A NI200900203A NI200900203A NI 200900203 A NI200900203 A NI 200900203A NI 200900203 A NI200900203 A NI 200900203A NI 200900203 A NI200900203 A NI 200900203A NI 200900203 A NI200900203 A NI 200900203A
Authority
NI
Nicaragua
Prior art keywords
antagonists
salts
piperazine salts
novel piperazine
solvates
Prior art date
Application number
NI200900203A
Other languages
English (en)
Inventor
Ágainé Csongor Éva
Domány György
Czibula Lászlo
Sebök Ferene
Greiner István
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of NI200900203A publication Critical patent/NI200900203A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a sales novedosas monohidrocloruro, dihidrocloruro, monohidrobromuro, maleato y metanosulfanato de trans 4 - { 2 - [ 4 - ( 2, 3 - diclorofenil ) - piperazin - 1 - il ] - etil } - N, N - dimetilcarbamoil - ciclohexilamina y/o sus hidratos y/o solvatos. Además, la invención se refiere al proceso de preparación de sales y sus hidratos y/o solvatos, a su uso en el tratamiento y/o prevención de trastornos que requieren la modulación de receptores de dopamina y a composiciones farmacéuticas que las contienen.
NI200900203A 2007-05-11 2009-11-09 Sales novedosas de piperazina como antagonistas d3/d2. NI200900203A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0700339A HU230748B1 (hu) 2007-05-11 2007-05-11 Új piperazin só és előállítási eljárása

Publications (1)

Publication Number Publication Date
NI200900203A true NI200900203A (es) 2010-03-11

Family

ID=89987512

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900203A NI200900203A (es) 2007-05-11 2009-11-09 Sales novedosas de piperazina como antagonistas d3/d2.

Country Status (35)

Country Link
US (1) US7943621B2 (es)
EP (1) EP2155696B1 (es)
JP (1) JP2010526861A (es)
KR (2) KR101668973B1 (es)
CN (1) CN101679315B (es)
AP (1) AP2009005012A0 (es)
AU (1) AU2008249772B2 (es)
BR (1) BRPI0811199A2 (es)
CA (1) CA2684404C (es)
CO (1) CO6241112A2 (es)
CY (1) CY1119076T1 (es)
DK (1) DK2155696T3 (es)
EA (1) EA017270B1 (es)
EC (1) ECSP099772A (es)
ES (1) ES2628025T3 (es)
GE (1) GEP20125522B (es)
HK (1) HK1140473A1 (es)
HR (1) HRP20170918T1 (es)
HU (2) HU230748B1 (es)
IL (1) IL201533A0 (es)
LT (1) LT2155696T (es)
MA (1) MA31434B1 (es)
MX (1) MX2009012182A (es)
MY (1) MY148078A (es)
NI (1) NI200900203A (es)
NZ (1) NZ580642A (es)
PL (1) PL2155696T3 (es)
PT (1) PT2155696T (es)
RS (1) RS56036B1 (es)
SI (1) SI2155696T1 (es)
TN (1) TN2009000458A1 (es)
TW (1) TWI424846B (es)
UA (1) UA102225C2 (es)
WO (1) WO2008139235A2 (es)
ZA (1) ZA200907511B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2155200T (pt) * 2007-05-11 2017-02-21 Richter Gedeon Nyrt Forma cristalina de um derivado de carbamoil-ciclohexano
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700369A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
WO2009020897A1 (en) * 2007-08-03 2009-02-12 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
ATE552002T1 (de) * 2008-02-21 2012-04-15 Richter Gedeon Nyrt Feste zubereitung zur oralen verabreichung
AP2975A (en) 2008-07-16 2014-09-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (hu) * 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
HU231227B1 (hu) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN106543105B (zh) * 2015-09-22 2019-10-11 江苏恩华药业股份有限公司 一种盐酸卡利拉嗪晶型ⅳ及其制备方法
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
WO2018229794A1 (en) 2017-06-13 2018-12-20 Cipla Limited Amorphous form of cariprazine
WO2019016828A1 (en) * 2017-07-15 2019-01-24 Msn Laboratories Private Limited, R&D Center NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N- {4- [2- [4- (2,3-DICHLOROPHENYL) PIPERAZIN-1-YL] ETHYL] CYCLOHEXYL} -N ', N'-DIMETHYLUMED HYDROCHLORIDE AND POLYMORPHS THIS ONE
WO2020056929A1 (zh) * 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
EP4206191A1 (en) * 2020-08-26 2023-07-05 Shanghai Bocimed Pharmaceutical Co., Ltd. Pharmaceutically acceptable salt of cariprazine and crystal form thereof, and preparation method therefor and use thereof
WO2023077094A1 (en) * 2021-10-28 2023-05-04 Abbvie Inc. Treatment of major depressive disorder
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HUP0500170A3 (en) * 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CO6241112A2 (es) 2011-01-20
LT2155696T (lt) 2017-06-12
US20090023750A1 (en) 2009-01-22
TWI424846B (zh) 2014-02-01
ZA200907511B (en) 2010-07-28
KR20150090264A (ko) 2015-08-05
HUE034796T2 (en) 2018-03-28
CY1119076T1 (el) 2018-01-10
WO2008139235A2 (en) 2008-11-20
HU0700339D0 (en) 2007-07-30
SI2155696T1 (sl) 2017-08-31
MX2009012182A (es) 2009-12-09
EA017270B1 (ru) 2012-11-30
TN2009000458A1 (en) 2011-03-31
US7943621B2 (en) 2011-05-17
EP2155696B1 (en) 2017-03-22
KR101668973B1 (ko) 2016-10-24
UA102225C2 (ru) 2013-06-25
AP2009005012A0 (en) 2009-10-31
MA31434B1 (fr) 2010-06-01
CA2684404A1 (en) 2008-11-20
EA200971046A1 (ru) 2010-04-30
HK1140473A1 (en) 2010-10-15
IL201533A0 (en) 2010-05-31
TW201002323A (en) 2010-01-16
HUP0700339A3 (en) 2010-01-28
PT2155696T (pt) 2017-06-02
HU230748B1 (hu) 2018-02-28
ES2628025T3 (es) 2017-08-01
ECSP099772A (es) 2009-12-28
GEP20125522B (en) 2012-05-25
HUP0700339A2 (en) 2009-04-28
RS56036B1 (sr) 2017-09-29
CN101679315B (zh) 2013-06-12
BRPI0811199A2 (pt) 2014-10-29
HRP20170918T1 (hr) 2017-09-22
MY148078A (en) 2013-02-28
PL2155696T3 (pl) 2017-10-31
KR20100018493A (ko) 2010-02-17
JP2010526861A (ja) 2010-08-05
CA2684404C (en) 2013-02-05
CN101679315A (zh) 2010-03-24
EP2155696A2 (en) 2010-02-24
NZ580642A (en) 2012-02-24
WO2008139235A3 (en) 2009-03-12
WO2008139235A8 (en) 2009-12-03
AU2008249772A1 (en) 2008-11-20
AU2008249772B2 (en) 2013-09-05
DK2155696T3 (en) 2017-07-10

Similar Documents

Publication Publication Date Title
NI200900203A (es) Sales novedosas de piperazina como antagonistas d3/d2.
NI200900202A (es) Metabolitos de derivados del (tio) - carbamoil - ciclohexano.
MY148643A (en) Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
SG170785A1 (en) Benzothiazoles having histamine h3 receptor activity
UY28765A1 (es) Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico
HRP20210486T1 (hr) Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje primarnih negativnih simptoma shizofrenije
CY1117638T1 (el) Παραγωγα του 2-(1,2,3-τριαζολ-2-υλο)βενζαμιδιου και του 3-(1,2,3-τριαζολ-2-υλο)πικολιναμιδιου ως ανταγωνιστες του υποδοχεα της ορεξινης
ATE449090T1 (de) Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
HRP20120263T1 (hr) Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje shizofrenije
ECSP11011468A (es) Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6
AR072242A1 (es) Derivados de imidazopiridina, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neuromusculares.
MX2021002111A (es) Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa.
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
AR063345A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)-piperidin-4-iliden)metil) benzamida para el tratamiento del dolor, ansiedad y depresion
EA202191620A1 (ru) Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения
CU20090190A7 (es) Sales novedosas de piperazina como antagonistas d3/d2
EA202091737A1 (ru) Производные индола и бензимидазола в качестве двойных антагонистов рецепторов 5-ht2a и 5-ht6
ATE496891T1 (de) Für die behandlung von neuropsychiatrischen störungen geeignete arylpiperazinderivate
ATE433444T1 (de) Pyroglutamatsalze und deren verwendung bei der optischen trennung von zwischenprodukten für die synthese von dextrocetirizin und levocetirizin
PL407397A1 (pl) 1,1-ditlenek 3-(4-bromobenzoilo)-4-hydroksy-2-{2-[4-(2-pirymidylo)piperazyn-1-ylo]-2-oksoetylo}-2H-1,2-benzotiazyny o aktywności przeciwzapalnej i przeciwbólowej oraz sposób jego wytwarzania
PL431466A1 (pl) Zastosowanie długołańcuchowej pochodnej arylopiperazyn JJ-AR-2 jako inhibitora nitryfikacji
PL431467A1 (pl) Zastosowanie długołańcuchowej pochodnej arylopiperazyn JJ-AR-12 jako inhibitora nitryfikacji
PL407396A1 (pl) 1,1-ditlenek 3-benzoilo-4-hydroksy-2-{2-[4-(2-metoksyfenylo)piperazyn-1-ylo]2-oksoetylo}-2H-1,2-benzotiazyny o aktywności przeciwzapalnej i przeciwbólowej oraz sposób jego wytwarzania
PL407398A1 (pl) 1,1-ditlenek 2-[2-(4-fenylopiperazyn-1-ylo)-2-oksoetylo]-4-hydroksy-3-(4-metylobenzoilo)-2H-1,2-benzotiazyny o aktywności przeciwbólowej i przeciwzapalnej oraz sposób jego wytwarzania
TH131527A (th) เกลือไพเพอราซีนชนิดใหม่ซึ่งเป็น d3/d2 แอนทาโกนิสต์